12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Alpharadin radium-223: Phase I/IIa ongoing

Algeta disclosed in its 3Q12 earnings that it and partner Bayer began the Phase IIa portion of the open-label, international Phase I/IIa BC1-10 trial evaluating docetaxel with and without Alpharadin. The...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >